Holen Sie sich die Stockscreener-App
2.07
0.00%
0.00
Schlusskurs vom Vortag:
$2.07
Offen:
$2.19
24-Stunden-Volumen:
69,893
Relative Volume:
0.49
Marktkapitalisierung:
$115.01M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.38M
KGV:
-5.3077
EPS:
-0.39
Netto-Cashflow:
$-25.19M
1W Leistung:
+3.50%
1M Leistung:
+82.39%
6M Leistung:
+110.02%
1J Leistung:
+95.28%
1-Tages-Spanne:
$2.01
$2.19
1-Wochen-Bereich:
$1.87
$2.31
52-Wochen-Spanne:
$0.51
$2.86
Connect Biopharma Holdings Ltd Adr Stock (CNTB) Company Profile
Firmenname
Connect Biopharma Holdings Ltd Adr
Sektor
Branche
Telefon
858-727-1040
Adresse
3580 CARMEL MOUNTAIN ROAD, SUITE 200, SAN DIEGO
Vergleichen Sie CNTB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNTB
Connect Biopharma Holdings Ltd Adr
|
2.07 | 118.35M | 0 | -21.38M | -25.19M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Connect Biopharma Holdings Ltd Adr Stock (CNTB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-12 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-03-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-13 | Eingeleitet | Jefferies | Buy |
| 2021-04-13 | Eingeleitet | Piper Sandler | Overweight |
| 2021-04-13 | Eingeleitet | SVB Leerink | Outperform |
Connect Biopharma Holdings Ltd Adr Aktie (CNTB) Neueste Nachrichten
Connect Biopharma Shares Rise on Plan to End ADR Program and Directly List on Nasdaq - MSN
What Makes Connect Biopharma Holdings Limited Sponsored ADR (CNTB) a Strong Momentum Stock: Buy Now? - Yahoo Finance
Research Analysts Set Expectations for CNTB Q2 Earnings - MarketBeat
Connect Biopharma (NASDAQ:CNTB) Upgraded at Northland Capmk - Defense World
Q2 Earnings Estimate for CNTB Issued By Northland Capmk - Defense World
Connect Biopharma stock rating reiterated as Outperform by Northland - Investing.com Australia
Connect Biopharma appoints Jim Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Connect Biopharma appoints Jim Schoeneck to board of directors - Investing.com Australia
Connect Biopharma appoints James A. Schoeneck to board of directors By Investing.com - Investing.com Nigeria
Northland starts Connect Biopharma at Outperform on chance to define new class - TipRanks
Connect Biopharma stock rises after announcing plan to terminate ADR program - Investing.com
Connect Biopharma to terminate ADR program, list ordinary shares By Investing.com - Investing.com India
Connect Biopharma to terminate ADR program, list ordinary shares - Investing.com
Connect Biopharma to Terminate ADR Program and List Ordinary Shares on Nasdaq - Nasdaq
Connect Biopharma Announces Plans to Terminate its American - GlobeNewswire
Connect Biopharma Streamlines Trading: ADRs Convert to Direct Nasdaq Shares in Major US Market Push - Stock Titan
Connect Biopharma Terminates ADS Agreement with Deutsche Bank - AInvest
Connect Biopharma to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewswire Inc.
Connect Biopharma regains Nasdaq compliance with minimum bid price rule - Investing.com India
Connect Biopharma regains Nasdaq compliance with minimum bid price rule By Investing.com - Investing.com South Africa
Connect Biopharma regains Nasdaq compliance with $1 minimum bid price - Investing.com
Connect Biopharma’s partner submits new drug application in China - Investing.com
Connect Biopharma’s partner submits new drug application in China By Investing.com - Investing.com South Africa
Connect Biopharma (NASDAQ:CNTB) Trading Down 2.5% – Here’s What Happened - Defense World
Connect Biopharma reports positive data for asthma treatment By Investing.com - Investing.com South Africa
Connect Biopharma reports positive data for asthma treatment - Investing.com
Connect Biopharma begins Phase 2 asthma study - Investing.com
Connect Biopharma stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa
Connect Biopharma stock hits 52-week low at $0.55 amid market challenges - Investing.com
FDA greenlights Connect Biopharma’s asthma and COPD trials - Investing.com
Connect Biopharma stock holds $8 target, Buy rating at H.C. Wainwright - Investing.com
Connect Biopharma shares rise 1.62% after-hours following positive FDA feedback on Phase 2 trials for asthma and COPD treatments. - AInvest
Connect Biopharma faces Nasdaq delisting over share price By Investing.com - Investing.com India
Connect Biopharma faces Nasdaq delisting over share price - Investing.com
Connect Biopharma stock hits 52-week low at $0.76 - Investing.com
Connect Biopharma stock hits 52-week low at $0.91 amid market challenges - Investing.com India
Form N-CSR FIDELITY CONCORD STREET For: Nov 30 - StreetInsider.com
Top 3 Aerospace and Defense Stocks Flying Under the Radar - The Globe and Mail
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year? - Nasdaq
Stocks Set to Open Lower as Investors Await Fed Meeting, Banking Sector Remains in Focus - Barchart.com
What should you do if you own US-listed Chinese stocks ordered by SEC to delist? - Dr Wealth
HFCAA News: 128 Chinese Stocks the SEC Could Delist - InvestorPlace
Making it harder to "buy" China, Inc. - USC-China Institute
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - Business Wire
CNTB News Today | Why did Connect Biopharma stock go down today? - MarketBeat
Connect Biopharma (CNTB) Stock Price, News & Analysis - MarketBeat
Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time - MarketBeat
52 Week HighUnited States Stocks - Investing.com
Finanzdaten der Connect Biopharma Holdings Ltd Adr-Aktie (CNTB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.24%
3.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):